F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 294 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Markets Direct's, 'F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2014', provides an overview of the F. Hoffmann-La Roche Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of F. Hoffmann-La Roche Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of F. Hoffmann-La Roche Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of F. Hoffmann-La Roche Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the F. Hoffmann-La Roche Ltd.'s pipeline products

Reasons to buy

- Evaluate F. Hoffmann-La Roche Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of F. Hoffmann-La Roche Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the F. Hoffmann-La Roche Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of F. Hoffmann-La Roche Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of F. Hoffmann-La Roche Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of F. Hoffmann-La Roche Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
F. Hoffmann-La Roche Ltd. Snapshot 7
F. Hoffmann-La Roche Ltd. Overview 7
Key Information 7
Key Facts 7
F. Hoffmann-La Roche Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
F. Hoffmann-La Roche Ltd. - Pipeline Review 17
Pipeline Products by Stage of Development 17
Pipeline Products - Monotherapy 18
Pipeline Products - Combination Treatment Modalities 19
Pipeline Products - Partnered Products 20
Pipeline Products - Out-Licensed Products 23
F. Hoffmann-La Roche Ltd. - Pipeline Products Glance 26
F. Hoffmann-La Roche Ltd. - Late Stage Pipeline Products 26
F. Hoffmann-La Roche Ltd. - Clinical Stage Pipeline Products 30
F. Hoffmann-La Roche Ltd. - Early Stage Pipeline Products 36
F. Hoffmann-La Roche Ltd. - Drug Profiles 39
alectinib 39
bevacizumab 41
obinutuzumab 46
omalizumab 48
tocilizumab 50
vemurafenib 53
cobimetinib + vemurafenib 56
gantenerumab 58
ibandronate sodium 60
lebrikizumab 62
ocrelizumab 64
onartuzumab 67
pertuzumab 70
ranibizumab 73
RG-7446 76
trastuzumab 78
trastuzumab emtansine 80
(danoprevir + ritonavir) 84
bitopertin 85
danoprevir 87
imgatuzumab 89
mericitabine 91
RG-1577 93
RG-1578 95
RG-1662 97
RG-7090 98
RG-7221 99
RG-7314 100
RG-7446 + bevacizumab 101
RG-7686 102
RG-7929 103
rituximab 104
RO-4998452 107
RO-5093151 108
setrobuvir 110
STX-107 112
TRX-1 113
vismodegib 114
ORY-1001 117
PRX-002 119
RG-7116 120
RG-7155 121
RG-7167 122
RG-7203 123
RG-7304 124
RG-7356 125
RG-7388 127
RG-7410 128
RG-7446 + cobimetinib 129
RG-7446 + vemurafenib 130
RG-7641 131
RG-7697 132
RG-7716 133
RG-7795 134
RG-7800 135
RG-7813 137
RG-7863 138
RO-5267683 139
RO-5285119 140
RO-5428029 141
RO-5508887 142
RO-5509554 143
RO-5545965 144
RO-6799477 145
RO-6836191 146
RO-6839921 147
RO-6864018 148
RO-6870868 149
Benzodiazepinone-36 150
Benzoxazepinone-40 151
Bispecific Antibodies For RSV 152
CLP-257 153
GAL-F2 154
IMA-930 155
IMA-942 156
INO-1800 158
INO-5150 160
MAR-531 161
Monoclonal Antibody Conjugates for Solid Tumors 162
RN-486 163
RO-2959 164
RO-4938581 165
RO-5073012 166
RO-5203280 167
Ro-646198 168
RO-6839328 169
RO-9021 170
Small Molecule to Activate GPR119 for Type II Diabetes 171
Small Molecules to Inhibit Janus Kinase 3 172
Small Molecules To Inhibit PTP1B 173
STX-110 174
XGFR-2 175
XGFR-4 176
Antisense Oligonucleotides for Undisclosed Indication 177
DARPins for Cancer 178
Fluoropyridone-19 179
Glycogen Synthase Activators 180
RG-7109 181
Small Molecules for Multi-Drug Resistant Gram-Negative Bacterial Infections 182
Small Molecules for Neuropsychiatric Disorders 183
Small Molecules Inhibiting DYRK1B for Cancer 184
Viral Polymerase Inhibitors 185
F. Hoffmann-La Roche Ltd. - Pipeline Analysis 186
F. Hoffmann-La Roche Ltd. - Pipeline Products by Target 186
F. Hoffmann-La Roche Ltd. - Pipeline Products by Route of Administration 192
F. Hoffmann-La Roche Ltd. - Pipeline Products by Molecule Type 193
F. Hoffmann-La Roche Ltd. - Pipeline Products by Mechanism of Action 195
F. Hoffmann-La Roche Ltd. - Recent Pipeline Updates 201
F. Hoffmann-La Roche Ltd. - Dormant Projects 253
F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products 261
Discontinued Pipeline Product Profiles 263
F. Hoffmann-La Roche Ltd. - Company Statement 275
F. Hoffmann-La Roche Ltd. - Locations And Subsidiaries 277
Head Office 277
Other Locations & Subsidiaries 277
Appendix 285
Methodology 285
Coverage 285
Secondary Research 285
Primary Research 285
Expert Panel Validation 285
Contact Us 286
Disclaimer 286

List of Tables
F. Hoffmann-La Roche Ltd., Key Information 15
F. Hoffmann-La Roche Ltd., Key Facts 15
F. Hoffmann-La Roche Ltd. - Pipeline by Indication, 2014 18
F. Hoffmann-La Roche Ltd. - Pipeline by Stage of Development, 2014 25
F. Hoffmann-La Roche Ltd. - Monotherapy Products in Pipeline, 2014 26
F. Hoffmann-La Roche Ltd. - Combination Treatment Modalities in Pipeline, 2014 27
F. Hoffmann-La Roche Ltd. - Partnered Products in Pipeline, 2014 28
F. Hoffmann-La Roche Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 29
F. Hoffmann-La Roche Ltd. - Out-Licensed Products in Pipeline, 2014 31
F. Hoffmann-La Roche Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 32
F. Hoffmann-La Roche Ltd. - Pre-Registration, 2014 34
F. Hoffmann-La Roche Ltd. - Filing rejected/Withdrawn, 2014 35
F. Hoffmann-La Roche Ltd. - Phase III, 2014 36
F. Hoffmann-La Roche Ltd. - Phase II, 2014 38
F. Hoffmann-La Roche Ltd. - Phase I, 2014 41
F. Hoffmann-La Roche Ltd. - Preclinical, 2014 44
F. Hoffmann-La Roche Ltd. - Discovery, 2014 46
F. Hoffmann-La Roche Ltd. - Pipeline by Target, 2014 195
F. Hoffmann-La Roche Ltd. - Pipeline by Route of Administration, 2014 200
F. Hoffmann-La Roche Ltd. - Pipeline by Molecule Type, 2014 202
F. Hoffmann-La Roche Ltd. - Pipeline Products by Mechanism of Action, 2014 204
F. Hoffmann-La Roche Ltd. - Recent Pipeline Updates, 2014 209
F. Hoffmann-La Roche Ltd. - Dormant Developmental Projects,2014 261
F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products, 2014 269
F. Hoffmann-La Roche Ltd., Subsidiaries 285